Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch (NASDAQ:RVMD)
· seekingalpha.com
Revolution Medicines (RVMD) Q2 2026 earnings call: daraxonrasib NDA accepted, EMA phase review, 2,000+ EAP patients, and higher 2026 spend—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...